HER2 Gene Mutation Not Yet Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0081068 (HER2 Gene Mutation)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06178445Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerTreatment